Retatrutide: what forty months of clinical trials have actually measured

The short version

Retatrutide is an experimental weight-loss and diabetes drug that has not been approved anywhere in the world. Think of it as a hormone-mimic that turns on three different metabolic switches at once — one that curbs appetite, one that helps the body handle blood sugar, and one that dials up calorie burning. In a Phase 2 trial of 338 adults with obesity, the highest dose produced a mean body-weight reduction of 24.2 percent over 48 weeks ^[1]. That is a larger drop than any other drug in this class has shown at a comparable stage. Eli Lilly, the company developing it, is now running larger Phase 3 trials — the TRIUMPH program — to confirm those results and check long-term safety. It is not a prescription drug and it is not available through pharmacies. The most common side effects in trials were nausea, vomiting, and diarrhea, which were dose-related and usually mild to moderate. What people have reported from research-use communities — including the downsides — is covered on the effects page.

What does retatrutide do

Retatrutide (LY3437943) is a 39-amino-acid synthetic peptide engineered to activate three hormone receptors simultaneously: the GLP-1 receptor (glucagon-like peptide-1 receptor, which suppresses appetite and stimulates insulin release), the GIP receptor (glucose-dependent insulinotropic polypeptide receptor, which further augments insulin and influences fat metabolism), and the glucagon receptor (GCGR, which increases energy expenditure and promotes hepatic fat breakdown). No single receptor covers all three jobs. By engaging all three at once, retatrutide drives weight loss through appetite suppression and increased calorie burning — the combination that makes its Phase 2 numbers stand apart ^[1][6].

In a 48-week Phase 2 obesity trial, mean body-weight change at the 12 mg dose was −24.2 percent versus −2.1 percent on placebo ^[1]. In a parallel 36-week Phase 2 diabetes trial, HbA1c (a blood-sugar marker, measured over roughly three months) fell by −2.02 percent at 12 mg versus −0.01 percent on placebo, while body weight fell −16.94 percent ^[2]. A Phase 2 substudy in MASLD (metabolic dysfunction-associated steatotic liver disease, the current term for fatty liver linked to metabolic risk factors) found liver-fat content reduced by −82.4 percent at 24 weeks at the highest dose, with 86 percent of participants reaching normal liver-fat levels ^[5].

A 2025 Biomolecules review characterizes those weight-loss numbers as a "step-change" relative to prior incretin therapies ^[6]. The reviewer is correct to note the caveat: this is Phase 2 data, drawn from tightly monitored clinical trials; Phase 3 results and regulatory submission are still pending.

How does retatrutide work

The mechanism rests on three receptor pathways firing in concert. Cryo-electron microscopy structures resolved in 2024 show retatrutide engaging GLP-1R, GIPR, and GCGR simultaneously, with relative potencies of approximately 0.4x native GLP-1, 8.9x native GIP, and 0.3x native glucagon ^[3]. The elevated GIPR potency is an intentional design choice: GIP receptor agonism appears to synergise with GLP-1 signaling on weight loss while softening GI side effects relative to GLP-1 agonism alone. The partial glucagon-receptor activity is the feature that distinguishes retatrutide most sharply from existing dual agonists — glucagon receptor (GCGR) activation raises basal energy expenditure and accelerates hepatic lipid clearance through cAMP/PKA signalling in liver and brown adipose tissue. Both effects contribute to the larger body-weight reduction seen at the highest doses ^[1][6].

The molecule is acylated with a C20 fatty-diacid chain for albumin binding, which extends its plasma half-life to approximately six days — the pharmacokinetic basis for once-weekly subcutaneous dosing ^[4].

Is retatrutide fda approved

No. Retatrutide is not approved by the FDA, the European Medicines Agency, or any other regulatory body as of mid-2026. It is an investigational compound in Phase 3 clinical trials. The TRIUMPH-1 trial (NCT05929066) is the pivotal Phase 3 obesity trial ^[7]; TRIUMPH-3 (NCT05882045) adds a cardiovascular-disease cohort ^[8]; and a dedicated cardiovascular and kidney outcomes trial (NCT06383390) examines long-term organ safety ^[9]. A head-to-head comparison against tirzepatide (NCT06662383) is also ongoing ^[10].

Approval requires successful Phase 3 data, followed by an NDA submission to the FDA, FDA review (typically 6–12 months after a complete submission), and an advisory committee decision before any labeling or commercial availability. None of those steps have occurred. Calling retatrutide "approved" or "available by prescription" would be factually incorrect. This site documents the published research record; it cannot and does not predict when or whether regulatory approval will occur. See the retatrutide availability page for detail on the trial timeline.

What the early-phase trials established

Phase 1b (NCT04143802) enrolled 72 adults with type 2 diabetes and tested once-weekly subcutaneous doses from 0.5 mg up to 3/6/9/12 mg in a stepwise multiple-ascending-dose design ^[11]. The study confirmed a half-life of approximately six days and a placebo-adjusted weight loss of −8.96 kg at the highest-dose cohort over 12 weeks ^[4]. Treatment-emergent adverse events were reported in 63 percent of participants, predominantly GI in nature; no serious safety signals halted the program.

For Retatrutide research depth, the full mechanism breakdown, Phase 2 results across all four dose arms, and the ongoing TRIUMPH Phase 3 program, see the research page. For Retatrutide effects — including what community researchers have reported and the documented safety cautions — see the effects page. The Retatrutide references page lists every citation with DOI and PubMed URL.